Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Achieve Life Sciences Inc (NQ: ACHV ) 4.510 +0.110 (+2.50%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Achieve Life Sciences Inc < Previous 1 2 Next > Life Science Virtual Investor Forum Presentations Now Available for Online Viewing March 08, 2024 Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024 March 05, 2024 Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire Life Science Investor Forum: Presentations Now Available for Online Viewing December 15, 2023 Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation March 29, 2023 Topline Data Expected in 2Q 2023 From Achieve Life Sciences Via GlobeNewswire Life Science Investor Forum Agenda Announced for December 14th, 2023 December 12, 2023 From Virtual Investor Conferences Via GlobeNewswire Achieve Life Sciences Inc. (NASDAQ: ACHV) Climbs to New 52-Week High April 26, 2023 Via Investor Brand Network Achieve Life Sciences Announces Refresh to Board of Directors March 30, 2023 From Achieve Life Sciences Via GlobeNewswire Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation March 08, 2023 Topline Data Expected in 2Q 2023 From Achieve Life Sciences Via GlobeNewswire Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting March 03, 2023 From Achieve Life Sciences Via GlobeNewswire Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023 March 02, 2023 From Achieve Life Sciences Via GlobeNewswire Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation February 07, 2023 Topline Data Expected in 2Q 2023 From Achieve Life Sciences Via GlobeNewswire Achieve Life Sciences Announces Granting of New Hire Inducement Award March 17, 2023 From Achieve Life Sciences Via GlobeNewswire Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference February 02, 2023 From Achieve Life Sciences Via GlobeNewswire Achieve Life Sciences Announces Granting of New Hire Inducement Award January 27, 2023 From Achieve Life Sciences Via GlobeNewswire Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation January 09, 2023 From Achieve Life Sciences Via GlobeNewswire Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation December 21, 2022 From Achieve Life Sciences Via GlobeNewswire Achieve Life Sciences Announces Private Placement of $18.9 Million November 15, 2022 From Achieve Life Sciences Via GlobeNewswire Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial November 08, 2022 Phase 2 ORCA-V1 Data Expected in 1H2023 From Achieve Life Sciences Via GlobeNewswire Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022 October 31, 2022 From Achieve Life Sciences Via GlobeNewswire 36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022 January 28, 2022 RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th - 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public... From MicroCap Rodeo Via AccessWire 36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022 May 16, 2022 RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public... From MicroCap Rodeo Via AccessWire Achieve Life Sciences to Participate in Upcoming Investor Conferences September 15, 2021 SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and... From Achieve Life Sciences, Inc. Via AccessWire Topics Death Exposures Death Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference September 14, 2021 SEATTLE, WA & VANCOUVER, BC / ACCESSWIRE / September 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and... From Achieve Life Sciences, Inc. Via AccessWire Topics Death Intellectual Property Exposures Death Intellectual Property Achieve Life Sciences to Participate in Two Upcoming Investor Conferences September 09, 2021 SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 9, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and... From Achieve Life Sciences, Inc. Via AccessWire Topics Death Exposures Death Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards August 13, 2021 SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and... From Achieve Life Sciences, Inc. Via AccessWire Topics Death Intellectual Property Exposures Death Intellectual Property Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update August 11, 2021 SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 12, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and... From Achieve Life Sciences, Inc. Via AccessWire Topics Death Intellectual Property Exposures COVID-19 Death Intellectual Property Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen August 11, 2021 SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and... From Achieve Life Sciences, Inc. Via AccessWire Topics Death Intellectual Property Exposures Death Intellectual Property Product Safety Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021 August 03, 2021 SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 3, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and... From Achieve Life Sciences, Inc. Via AccessWire Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use July 22, 2021 SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / July 22, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization... From Achieve Life Sciences, Inc. Via AccessWire Topics Death Intellectual Property Exposures Death Intellectual Property Product Safety Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline June 29, 2021 ORCA-2 Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo in Adult Smokers in the United States SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE /... From Achieve Life Sciences, Inc. Via AccessWire Topics Death Intellectual Property Exposures Death Intellectual Property Product Safety < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.